Research ExplorerPublicationsSurvivin is not an independent prognostic factor for patient...

Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study

Standard

Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. / Mathieu, Romain; Klatte, Tobias; Margulis, Vitaly; Karam, Jose A; Rouprêt, Morgan; Seitz, Christian; Karakiewicz, Pierre I; Fajkovic, Harun; Wood, Christopher G; Weizer, Alon Z; Raman, Jay D; Remzi, Mesut; Rioux-Leclercq, Nathalie; Haitel, Andrea; Bensalah, Karim; Lotan, Yair; Rink, Michael; Kluth, Luis A; Scherr, Douglas S; Robinson, Brian D; Shariat, Shahrokh F.

In: UROL ONCOL-SEMIN ORI, Vol. 33, No. 11, 11.2015, p. 495.e15-22.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mathieu, R, Klatte, T, Margulis, V, Karam, JA, Rouprêt, M, Seitz, C, Karakiewicz, PI, Fajkovic, H, Wood, CG, Weizer, AZ, Raman, JD, Remzi, M, Rioux-Leclercq, N, Haitel, A, Bensalah, K, Lotan, Y, Rink, M, Kluth, LA, Scherr, DS, Robinson, BD & Shariat, SF 2015, 'Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study', UROL ONCOL-SEMIN ORI, vol. 33, no. 11, pp. 495.e15-22. https://doi.org/10.1016/j.urolonc.2015.06.016

APA

Mathieu, R., Klatte, T., Margulis, V., Karam, J. A., Rouprêt, M., Seitz, C., Karakiewicz, P. I., Fajkovic, H., Wood, C. G., Weizer, A. Z., Raman, J. D., Remzi, M., Rioux-Leclercq, N., Haitel, A., Bensalah, K., Lotan, Y., Rink, M., Kluth, L. A., Scherr, D. S., ... Shariat, S. F. (2015). Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. UROL ONCOL-SEMIN ORI, 33(11), 495.e15-22. https://doi.org/10.1016/j.urolonc.2015.06.016

Vancouver

Mathieu R, Klatte T, Margulis V, Karam JA, Rouprêt M, Seitz C et al. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. UROL ONCOL-SEMIN ORI. 2015 Nov;33(11):495.e15-22. https://doi.org/10.1016/j.urolonc.2015.06.016

Bibtex

@article{26d645d52f9940b38c64d30a145697ab,
title = "Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study",
abstract = "OBJECTIVE: Several small single-center studies have reported conflicting results on the prognostic value of survivin expression in upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy. We attempted to validate the prognostic utility of survivin using a large multi-institutional cohort.MATERIAL AND METHODS: Survivin expression was evaluated by immunohistochemistry in tumor tissue from 732 patients with unilateral, sporadic UTUC treated with radical nephroureterectomy between 1990 and 2008 at 7 centers. Survivin expression was considered altered when at least 10% of the tumor cells stained positive. Associations of altered survivin expression with recurrence-free survival (RFS) and cancer-specific survival (CSS) were evaluated using Cox proportional hazards regression models.RESULTS: Altered survivin expression was observed in 288 (39.3%) tumors and was associated with more advanced pathological tumor stages (P<0.001), lymph node metastases (P<0.001), lymphovascular invasion (P<0.001), tumor necrosis (P = 0.027), and tumor architecture (P<0.001). Median follow-up was 35 (16-64) months. There were 191 (25.4%) patients who experienced disease recurrence, and 165 patients (21.9%) died of the disease. In the univariable analysis, altered survivin expression was significantly associated with worse RFS and CSS (each P<0.001); however, altered survivin expression did not achieve independent predictive status on multivariable models (P = 0.24 and P = 0.53). Similarly, survivin was not independently associated with outcomes in subgroup analyses, including patients with high-grade tumors.CONCLUSIONS: In UTUC, altered survivin expression is associated with worse clinicopathological features and worse RFS and CSS. However, it does not appear to be independently associated with cancer outcomes when considering standard prognostic factors.",
author = "Romain Mathieu and Tobias Klatte and Vitaly Margulis and Karam, {Jose A} and Morgan Roupr{\^e}t and Christian Seitz and Karakiewicz, {Pierre I} and Harun Fajkovic and Wood, {Christopher G} and Weizer, {Alon Z} and Raman, {Jay D} and Mesut Remzi and Nathalie Rioux-Leclercq and Andrea Haitel and Karim Bensalah and Yair Lotan and Michael Rink and Kluth, {Luis A} and Scherr, {Douglas S} and Robinson, {Brian D} and Shariat, {Shahrokh F}",
note = "Copyright {\textcopyright} 2015 Elsevier Inc. All rights reserved.",
year = "2015",
month = nov,
doi = "10.1016/j.urolonc.2015.06.016",
language = "English",
volume = "33",
pages = "495.e15--22",
journal = "UROL ONCOL-SEMIN ORI",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "11",

}

RIS

TY - JOUR

T1 - Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study

AU - Mathieu, Romain

AU - Klatte, Tobias

AU - Margulis, Vitaly

AU - Karam, Jose A

AU - Rouprêt, Morgan

AU - Seitz, Christian

AU - Karakiewicz, Pierre I

AU - Fajkovic, Harun

AU - Wood, Christopher G

AU - Weizer, Alon Z

AU - Raman, Jay D

AU - Remzi, Mesut

AU - Rioux-Leclercq, Nathalie

AU - Haitel, Andrea

AU - Bensalah, Karim

AU - Lotan, Yair

AU - Rink, Michael

AU - Kluth, Luis A

AU - Scherr, Douglas S

AU - Robinson, Brian D

AU - Shariat, Shahrokh F

N1 - Copyright © 2015 Elsevier Inc. All rights reserved.

PY - 2015/11

Y1 - 2015/11

N2 - OBJECTIVE: Several small single-center studies have reported conflicting results on the prognostic value of survivin expression in upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy. We attempted to validate the prognostic utility of survivin using a large multi-institutional cohort.MATERIAL AND METHODS: Survivin expression was evaluated by immunohistochemistry in tumor tissue from 732 patients with unilateral, sporadic UTUC treated with radical nephroureterectomy between 1990 and 2008 at 7 centers. Survivin expression was considered altered when at least 10% of the tumor cells stained positive. Associations of altered survivin expression with recurrence-free survival (RFS) and cancer-specific survival (CSS) were evaluated using Cox proportional hazards regression models.RESULTS: Altered survivin expression was observed in 288 (39.3%) tumors and was associated with more advanced pathological tumor stages (P<0.001), lymph node metastases (P<0.001), lymphovascular invasion (P<0.001), tumor necrosis (P = 0.027), and tumor architecture (P<0.001). Median follow-up was 35 (16-64) months. There were 191 (25.4%) patients who experienced disease recurrence, and 165 patients (21.9%) died of the disease. In the univariable analysis, altered survivin expression was significantly associated with worse RFS and CSS (each P<0.001); however, altered survivin expression did not achieve independent predictive status on multivariable models (P = 0.24 and P = 0.53). Similarly, survivin was not independently associated with outcomes in subgroup analyses, including patients with high-grade tumors.CONCLUSIONS: In UTUC, altered survivin expression is associated with worse clinicopathological features and worse RFS and CSS. However, it does not appear to be independently associated with cancer outcomes when considering standard prognostic factors.

AB - OBJECTIVE: Several small single-center studies have reported conflicting results on the prognostic value of survivin expression in upper tract urothelial carcinoma (UTUC) following radical nephroureterectomy. We attempted to validate the prognostic utility of survivin using a large multi-institutional cohort.MATERIAL AND METHODS: Survivin expression was evaluated by immunohistochemistry in tumor tissue from 732 patients with unilateral, sporadic UTUC treated with radical nephroureterectomy between 1990 and 2008 at 7 centers. Survivin expression was considered altered when at least 10% of the tumor cells stained positive. Associations of altered survivin expression with recurrence-free survival (RFS) and cancer-specific survival (CSS) were evaluated using Cox proportional hazards regression models.RESULTS: Altered survivin expression was observed in 288 (39.3%) tumors and was associated with more advanced pathological tumor stages (P<0.001), lymph node metastases (P<0.001), lymphovascular invasion (P<0.001), tumor necrosis (P = 0.027), and tumor architecture (P<0.001). Median follow-up was 35 (16-64) months. There were 191 (25.4%) patients who experienced disease recurrence, and 165 patients (21.9%) died of the disease. In the univariable analysis, altered survivin expression was significantly associated with worse RFS and CSS (each P<0.001); however, altered survivin expression did not achieve independent predictive status on multivariable models (P = 0.24 and P = 0.53). Similarly, survivin was not independently associated with outcomes in subgroup analyses, including patients with high-grade tumors.CONCLUSIONS: In UTUC, altered survivin expression is associated with worse clinicopathological features and worse RFS and CSS. However, it does not appear to be independently associated with cancer outcomes when considering standard prognostic factors.

U2 - 10.1016/j.urolonc.2015.06.016

DO - 10.1016/j.urolonc.2015.06.016

M3 - SCORING: Journal article

C2 - 26228160

VL - 33

SP - 495.e15-22

JO - UROL ONCOL-SEMIN ORI

JF - UROL ONCOL-SEMIN ORI

SN - 1078-1439

IS - 11

ER -